Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
Launched by PRABESH KANEL ·
Trial Information
Current as of September 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a supplement called tributyrin can help improve memory, thinking, walking, and balance in adults who have Parkinson’s disease or Parkinson’s disease dementia. Researchers want to find out if taking tributyrin is safe and if it helps with these symptoms compared to a placebo, which is a harmless pill that doesn’t contain the active supplement.
People who join the study will take tributyrin three times a day for about 3 months. Before and after this period, they will come to the clinic for tests that check their thinking and movement abilities, as well as have brain scans to see if there are any changes. This trial is open to adults with Parkinson’s disease or related memory problems. If you or a loved one fits this description and are interested, this study might offer a chance to try a new treatment while helping researchers learn more about managing Parkinson’s symptoms.
Gender
ALL
Eligibility criteria
About Prabesh Kanel
Prabesh Kanel is a clinical trial sponsor dedicated to advancing medical research through the support and oversight of innovative clinical studies. Committed to upholding the highest standards of scientific integrity and patient safety, Prabesh Kanel collaborates with research institutions and healthcare professionals to facilitate the development of novel therapies and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Prabesh Kanel, PhD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported